Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab for Chronic GvHD
NCT05604742Phase 2Withdrawn
- Sponsor
- Xuna
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of belimumab in chronic graft-versus-host disease (cGVHD) (3 arms), sponsored by Xuna. Primary endpoint: Overall Response Rate at 6 months. Planned start Jan 2022; status: withdrawn.
02
Drugs
belimumab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05604742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604742.